Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BMS-986156 |
Synonyms | |
Therapy Description |
BMS-986156 is an activating monoclonal antibody that binds to TNFRSF18 (GITR, CD357), which leads to the activation of effector T cells and a decrease in T-regulatory cells, subsequently resulting in antitumor activity (Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 104-104, PMID: 31697308). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BMS-986156 | BMS986156|BMS 986156 | GITR Antibody 7 | BMS-986156 is an activating monoclonal antibody that binds to TNFRSF18 (GITR, CD357), which leads to the activation of effector T cells and a decrease in T-regulatory cells, subsequently resulting in antitumor activity (Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 104-104, PMID: 31697308). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02598960 | Phase Ib/II | Nivolumab BMS-986156 | A Study of BMS-986156 Given Alone and in Combination With Nivolumab in Subjects With Advanced Solid Tumors | Completed | USA | NLD | ITA | FRA | ESP | DEU | CHE | CAN | BEL | AUS | 0 |